CLBTBy Calypso Research8 min read

Cellebrite (CLBT) Q4 2025 Earnings Analysis

Data Dilemmas: Cellebrite's Earnings Take a Hit at 4.6%

Key Takeaways

Cellebrite (CLBT) reported Q4 2025 earnings with revenue of $129M, representing a +18.1% year-over-year change. The stock moved -4.6% on earnings day.

The bull case: Re-accelerating ARR driven by federal recovery, AI-enabled analytics, and high-growth adjacencies like drones and D&I, all while sustaining >30% free cash flow margins, supports a durable compounder story.

The bear case: Execution, integration, and procurement risks around federal, AI monetization, and new M&A could limit upside to growth and margins, exposing the stock if large deals slip or AI and drone opportunities underdeliver versus expectations.

Financial Highlights

  • Revenue: $129M (+18.1% YoY)
  • Gross Profit: $109M (84.7% margin, +0.9% YoY)
  • Operating Income: $21M (16.2% margin, +1.7% YoY)
  • Net Income: $21M
  • TTM Revenue: $476M

Stock Performance

  • Earnings Day Move: -4.6%
  • Year-to-Date: -33.1%
  • 1-Year Return: -37.0%
  • vs. S&P 500 (since earnings): -29.0%
  • vs. Nasdaq (since earnings): -26.8%

View live CLBT data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Cellebrite's Q4 2025 earnings call:

Sustainability and Drivers of ARR Re‑acceleration (Including US Federal Recovery)

Sentiment: Positive

"Our initial view into 2026 ARR calls for a reacceleration in our growth rate versus the 17% organic expansion we delivered in 2025... we focused on setting prudent ARR and revenue expectations around tighter ranges that are corroborated by our renewals, deal pipeline, and applicable RPO coverage." — David Barter
"We have scoped an initial contract for a large federal agency in their storage requirements, which exceeds nine petabytes... that would equate to a very large deal that would that would be certainly the single biggest transaction we would have ever done... we want to get through the ATO process... and then we will talk about turning that into real revenue as quickly as we possibly can." — Marcus Jewell

M&A Strategy and Integration Risk (Keryllium & SCG Canada / Drone Forensics)

Sentiment: Positive

"Instead of using our devices on UFEDS to extract forensic data from phones, we're now using their CFID to extract forensics from a drone... this couldn't be more sort of core and complementary to who we are and what we do. So the dive difficulty here is actually you know, relative to a standard acquisition, the dive difficulty here is low." — Thomas E. Hogan
"We're inheriting a low single digit ARR run rate... we'll be in the $15 to $20 million range for the company. And then... it will be disappointed in the midterm if the the ARR growth potential for that business isn't well north of that $15 to $20 million... we're hitting this at the right time." — Thomas E. Hogan

AI Strategy, Monetization, and Competitive Impact

Sentiment: Positive

"We are working on [monetization] real time... one of the messages I would give to the shareholder base is candidly, the guidance that we have in place today assumes... that we don't monetize any of that in '26... based on the feedback we're getting, I actually think there is gonna be an opportunity... to start to monetize some of these AgenTeq applications." — Thomas E. Hogan
"Given the nuance of what we do, the specific use cases, the complexity of the data on phones, this is not some standard research or task that a lot of these engines are capable [of] essentially outsourcing... this is why we think AI for Cellebrite... is actually a tailwind and a force multiplier for us." — Thomas E. Hogan

US Federal and Defense/Intelligence (“D&I”) Opportunity and Execution

Sentiment: Positive

"Border security continues to be across the world, a big area. And a lot of money is going into that... there's a World Cup FIFA World Cup coming to The US... and we are used in in the deployment of those areas... And then the final point... will be the ATO... for our Guardian solution, which means we are unique in a position the only people that can actually store and share forensic data under the FedRAMP approval." — Marcus Jewell
"We have multiple threads of large annual spend in in the first and second half of this year... I'd like you to think about that. There's not one single customer that's actually three or four different programs which are all in 7 figures for us." — Marcus Jewell

Guidance Philosophy, Margin Headwinds, and Free Cash Flow Durability

Sentiment: Positive

"We now view 25% adjusted EBITDA as our new floor on profitability... we'll be using ARR growth and FCF margin to measure our rule of x... we begin the year with an outlook in the upper forties and an objective to drive performance to 50 plus." — David Barter
"It's about a point of compression on margins due to Keryllium... and FX a healthy... it's more than a point, that that's ultimately burdening the p and l... we ended the year with a pretty healthy hedge... we are taking on a healthy point of compression just due to the strength of the shekel." — David Barter

Bull Case

Re-accelerating ARR driven by federal recovery, AI-enabled analytics, and high-growth adjacencies like drones and D&I, all while sustaining >30% free cash flow margins, supports a durable compounder story.

Bear Case

Execution, integration, and procurement risks around federal, AI monetization, and new M&A could limit upside to growth and margins, exposing the stock if large deals slip or AI and drone opportunities underdeliver versus expectations.

Looking Ahead

With revenue growing +18.1% year-over-year, the key question is whether Cellebrite can sustain this growth trajectory, particularly around sustainability and Drivers of ARR Re‑acceleration (Including US Federal Recovery). With operating margins at 16.2%, margin trends will remain a focal point. The market's negative earnings-day reaction signals that investors need to see stronger execution, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Cellebrite's revenue in Q4 2025?

Cellebrite reported Q4 2025 revenue of $129M, representing a +18.1% year-over-year change.

Did Cellebrite beat earnings expectations in Q4 2025?

The stock declined -4.6% on earnings day, suggesting the results fell short of market expectations. The current bull case centers on: Re-accelerating ARR driven by federal recovery, AI-enabled analytics, and high-growth adjacencies like drones and D&I, all while sustaining >30% free cash flow margins, supports a durable compounder story.

What is the bull case for CLBT stock?

The bull case for CLBT centers on: Re-accelerating ARR driven by federal recovery, AI-enabled analytics, and high-growth adjacencies like drones and D&I, all while sustaining >30% free cash flow margins, supports a durable compounder story.

What is the bear case for CLBT stock?

The bear case for CLBT centers on: Execution, integration, and procurement risks around federal, AI monetization, and new M&A could limit upside to growth and margins, exposing the stock if large deals slip or AI and drone opportunities underdeliver versus expectations.

How has CLBT stock performed since its Q4 2025 earnings?

CLBT moved -4.6% on the day of its Q4 2025 earnings report, underperforming the S&P 500 by +29.0% since earnings. Year-to-date, the stock has returned -33.1%.

Browse all 400+ earnings reports →

Learn More

Analyze CLBT in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Cellebrite and 400+ other stocks, explore the full platform.

Open CLBT on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.